Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interfant-21 for infants with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
2022-502503-30-00Phase 3Authorised
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Dec 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 28
01
Overview
Phase 3, open-label, single-arm trial of blinatumomab, asparaginase escherichia coli, dexamethasone, mercaptopurine, methotrexate and 10 more in acute lymphoblastic leukemia (ALL) and mixed phenotype acute leukemia (MPAL), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Event-free survival. Planned start Dec 2022; status: authorised.
02
Drugs
blinatumomabasparaginase escherichia colidexamethasonemercaptopurinemethotrexate
03
Conditions
acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on 2022-502503-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502503-30-00.